Compounds selected from: ##STR00001## where DRUG-OH, DRUG-COOH and DRUG-NH.sub.2 are biologically active compounds; each X is independently selected from --CH.sub.2COO-- (glycolic acid moiety), --CH(CH.sub.3)COO-- (lactic acid moiety), --CH.sub.2CH.sub.2OCH.sub.2COO-- (dioxanone moiety), --CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2COO-- (caprolactone moiety), --(CH.sub.2).sub.yCOO--, where y is 2-4 or 6-24 and --(CH.sub.2CH.sub.2O).sub.zCH.sub.2COO--, where z is 2-24; each Y is independently selected from --COCH.sub.2O-- (glycolic ester moiety), --COCH(CH.sub.3)O-- (lactic ester moiety), --COCH.sub.2OCH.sub.2CH.sub.2O-- (dioxanone ester moiety), --COCH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2O-- (caprolactone ester moiety), --CO(CH.sub.2).sub.mO--, where m is 2-4 or 6-24 and --COCH.sub.2O(CH.sub.2CH.sub.2O).sub.n-- where n is between 2-24; R' is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.

 
Web www.patentalert.com

< MODIFIED-RELEASE FORMULATIONS OF AZABICYCLO DERIVATIVES

< SYSTEMS FOR AND METHODS OF MEDICAL SCHEDULING BASED ON SIMULATION-BASED OPTIMIZATION

> Drug or Supplement Combination with Conjugated Linoleic Acid for Fat Loss in Mammals

> DIACYLGLYCEROL ACYLTRANSFERASE ASSAY

~ 00613